中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

465 records (took 0.053 seconds)

    Container with ramp action closure
    94.
    发明授权
    Container with ramp action closure 失效
    集装箱与斜坡动作关闭

    公开(公告)号：US5715960A

    公开(公告)日：1998-02-10

    申请号：US318613

    申请日：1994-10-06

    Applicant: Richard William Seymour

    Inventor： Richard William Seymour

    IPC: B65D20060101 ,  B65D41/17 ,  B65D43/10

    CPC classification number: B65D41/17

    Abstract: A container and closure combination wherein the closure comprises a skirt portion, the periphery of which has at least one rounded ramped portion adapted to cooperate with one or more corresponding rounded ramped portions on the container such that relative axial rotation of the container causes cooperation of the ramped portions and disengagement of the closure from the container.

    Abstract translation: PCT No.PCT / GB93 / 00724 Sec。 371日期：1994年10月6日 102（e）日期1994年10月6日PCT提交1993年4月6日PCT公布。 出版物WO93 / 21079 日期：1993年10月28日一种容器和闭合组合，其中所述封闭件包括裙部，所述裙部的周边具有至少一个圆形倾斜部分，其适于与所述容器上的一个或多个相应的圆形倾斜部分配合， 容器引起斜坡部分的合作和封闭物从容器的分离。

    Indole and indoline derivatives as 5HT.sub.1D receptor antagonists
    95.
    发明授权
    Indole and indoline derivatives as 5HT.sub.1D receptor antagonists 失效
    吲哚和二氢吲哚衍生物作为5HT1D受体拮抗剂

    公开(公告)号：US5696122A

    公开(公告)日：1997-12-09

    申请号：US605022

    申请日：1996-02-26

    Applicant: Laramie Mary Gaster ,  David Malcolm Duckworth ,  Sarah Margaret Jenkins ,  Paul Adrian Wyman

    Inventor： Laramie Mary Gaster ,  David Malcolm Duckworth ,  Sarah Margaret Jenkins ,  Paul Adrian Wyman

    IPC: A61K31/495 ,  A61K31/496 ,  A61P1/00 ,  A61P9/08 ,  A61P9/12 ,  A61P25/00 ,  A61P25/24 ,  A61P25/26 ,  A61P43/00 ,  C07D209/08 ,  C07D401/10 ,  C07D409/06 ,  C07D413/10 ,  C07D403/10 ,  C07D403/14 ,  C07D413/14

    CPC classification number: C07D401/10 ,  C07D209/08 ,  C07D409/06 ,  C07D413/10

    Abstract: The present invention provides novel indole and indoline derivatives according to formula (I) below, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments. The present indole and indoline derivatives are compounds of formula (I) or a salt thereof: ##STR1## in which R is a group of formula (i): ##STR2## in which P.sup.1 is a phenyl or a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur; and R.sup.1 and R.sup.2 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyC.sub.1-6 alkyl, acyl, nitro, trifluoromethyl, cyano, SR.sup.5, SOR.sup.5, SO.sub.2 R.sup.5, SO.sub.2 NR.sup.5 R.sup.6, CO.sub.2 R.sup.5, CONR.sup.5 R.sup.6, CONR.sup.5 (CH.sub.2).sub.x CO.sub.2 R.sup.6, NR.sup.5 R.sup.6, NR.sup.5 CO.sub.2 R.sup.6, CR.sup.5 =NOR.sup.6, where R.sup.5 and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl and x is 1 to 3; or R is a group of formula (ii): ##STR3## in which P.sup.2 is phenyl or biphenyl; P.sub.3 is phenyl or a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur; A is a bond or a group (CH.sub.2).sub.p --R.sup.8 --(CH.sub.2).sub.q where R.sup.8 is oxygen, S(O).sub.m where m is 0 to 2, carbonyl, CO.sub.2 or CH.sub.2 and p and q are independently 0 to 3; and R.sup.1 and R.sup.2 are as defined above in formula (i); R.sup.3 is hydrogen, halogen, hydroxy, C.sub.1-6 alkyl or C.sub.1-6 alkoxy;n is 1 or 2; R.sup.4 is hydrogen or C.sub.1-6 alkyl; and B is --CHR.sup.9 CHR.sup.10 -- or --CR.sup.9 .dbd.CR.sup.10 -- where R.sup.9 and R.sup.10 are independently hydrogen or C.sub.1-6 alkyl. C.sub.1-6 alkyl groups, whether alone or as part of another group, may be straight chain or branched. The groups P.sub.1, P.sub.2, and P.sub.3 can be aromatic or saturated heterocyclic rings.

    Abstract translation: PCT No.PCT / EP94 / 02663 371日期1996年2月26日 102（e）日期1996年2月26日PCT 1994年8月9日PCT公布。 公开号WO95 / 06637 日期1995年3月9日本发明提供了下述式（I）的新型吲哚和二氢吲哚衍生物，其制备方法，含有它们的药物组合物及其作为药物的用途。 本发明的吲哚和二氢吲哚衍生物是式（I）化合物或其盐：其中R是式（i）的基团：其中P1是苯基或 含有1至3个选自氧，氮或硫的杂原子的5至7元杂环; 酰基，硝基，三氟甲基，氰基，SR5，SOR5，SO2R5，SO2NR5R6，CO2R5，CONR5R6，CONR5（CH2）xCO2R6，NR5R6， NR5CO2R6，CR5 = NOR6，其中R5和R6独立地为氢或C1-6烷基，x为1至3; 或R为式（ⅱ）的基团：其中P2为苯基或联苯基;（ⅱ） P3是苯基或含有1至3个选自氧，氮或硫的杂原子的5至7元杂环; A是键或基团（CH 2）p -R 8 - （CH 2）q，其中R 8是氧，S（O）m，其中m是0至2，羰基，CO 2或CH 2，p和q独立地是0至3; 并且R 1和R 2如上述式（ⅰ）中所定义; R3是氢，卤素，羟基，C1-6烷基或C1-6烷氧基; n为1或2; R4是氢或C1-6烷基; 且B为-CHR 9 CHR 10 - 或-CR 9 = CR 10 - 其中R 9和R 10独立地为氢或C 1-6烷基。 不管是单独还是作为另一基团的一部分，C 1-6烷基可以是直链或支链的。 基团P1，P2和P3可以是芳族或饱和的杂环。

    Medicaments
    97.
    发明授权
    Medicaments 失效
    药剂

    公开(公告)号：US5637611A

    公开(公告)日：1997-06-10

    申请号：US442719

    申请日：1995-05-15

    Applicant: Francis D. King ,  Laramie M. Gaster ,  Alberto J. Kaumann ,  Rodney C. Young

    Inventor： Francis D. King ,  Laramie M. Gaster ,  Alberto J. Kaumann ,  Rodney C. Young

    IPC: A61K31/40 ,  A61K31/403 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/454 ,  A61P25/04 ,  A61P25/06 ,  A61P43/00 ,  C07D20060101 ,  C07D209/88 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D209/82

    CPC classification number: C07D209/88

    Abstract: Use of a compound of general formula (I): ##STR1## wherein: R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino (CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino (CH.sub.2).sub.n ;R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl;R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring;n represents 0, 1 or 2; andR.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring;or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

    Abstract translation: 通式（I）的化合物：其中：R 1表示氢，卤素，三氟甲基，硝基，羟基，C 1-6烷基，C 1-6烷氧基，芳基C 1-6烷氧基，-CO 2 R 4， - （CH 2 ）nCN， - （CH 2）nCONR 5 R 6， - （CH 2）n SO 2 NR 5 R 6，C 1-6烷酰基氨基（CH 2）n或C 1-6烷基磺酰基氨基（CH 2）n; R 4表示氢，C 1-6烷基或芳基C 1-6烷基; R 5和R 6各自独立地表示氢或C 1-6烷基，或者R 5和R 6与它们所连接的氮原子一起形成环; n表示0,1或2; 并且R 2和R 3各自独立地表示氢，C 1-6烷基或苄基，或与它们所连接的氮原子一起形成吡咯烷子基，哌啶子基或六氢氮杂环; 或其生理上可接受的盐在制备用于治疗其中指示5-HT1样激动剂的病症的药物中，例如偏头痛。 还描述了新的式（I）化合物，其制备方法和含有它们的药物组合物。

Patent Agency Ranking